Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.

Breast Cancer

Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.

Herceptin

225 mg/m^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.

Taxol

500 mg/m^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.

Fluorouracil

500 mg/m^2 on Day 1 of each cycle for 4 cycles.

Cytoxan

75 mg/m^2 IV on Day 1 of each cycle for 4 cycles.

Epirubicin

The University of Texas M.D.Anderson Cancer Center

UT MD Anderson Cancer Center

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Response criteria for Complete Remission defined as disappearance of all clinical evidence of active tumor by clinical evaluation, mammogram and/or ultrasound, and free of all symptoms.

M.D. Anderson Cancer Center

Genentech, Inc.

Breast Neoplasms

Fever

Hematologic Diseases

Neutropenia

Sepsis

FLAC chemotherapy with GM-CSF

National Cancer Institute (NCI)

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

taxol/fever

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

科学に裏打ちされた最も完全な薬草データベース